<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01250925</url>
  </required_header>
  <id_info>
    <org_study_id>10-04-029</org_study_id>
    <nct_id>NCT01250925</nct_id>
  </id_info>
  <brief_title>Effect of Contact Lens Wear on Immune Cell Density and Morphology of the Ocular Surface</brief_title>
  <official_title>Effect of Contact Lens Wear on Immune Cell Density and Morphology of the Ocular Surface: A Laser In Vivo Confocal Microscopy Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts Eye and Ear Infirmary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts Eye and Ear Infirmary</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to utilize in-vivo confocal microscopy to describe differences
      in corneal epithelial immune status across three lens care regimens in new contact lens
      wearers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An estimated 40 million people in the United States wear contact lenses, with approximately
      38 million soft lens wearers and 2 million rigid gas permeable lens wearers. The ocular
      surface has been shown to respond to the introduction of foreign materials with upregulation
      of proinflammatory mediators, leading to an increase in inflammation. The corneal can show a
      foreign body immune response to contact lenses. The purpose of this study is to utilize
      in-vivo confocal microscopy to describe differences in corneal epithelial immune status
      across the three lens care regimens in new contact lens wearers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Corneal Epithelial Immune Dendritic Cell Density (Central Cornea)</measure>
    <time_frame>Six weeks</time_frame>
    <description>The primary statistical objective is to describe differences in efficacy between regimens, specifically for measures of epithelial immune status. Immune status will be assessed via density of dendritic and non-dendritic immune cells.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Corneal Epithelial Immune Dendritic Cell Density (Inferior Cornea)</measure>
    <time_frame>Six weeks</time_frame>
    <description>The primary statistical objective is to describe differences in efficacy between regimens, specifically for measures of epithelial immune status. Immune status will be assessed via density of dendritic and non-dendritic immune cells.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Corneal Epithelial Immune Dendritic Cell Density (Nasal Cornea)</measure>
    <time_frame>Six weeks</time_frame>
    <description>The primary statistical objective is to describe differences in efficacy between regimens, specifically for measures of epithelial immune status. Immune status will be assessed via density of dendritic and non-dendritic immune cells.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Corneal Epithelial Immune Dendritic Cell Density (Superior Cornea)</measure>
    <time_frame>Six weeks</time_frame>
    <description>The primary statistical objective is to describe differences in efficacy between regimens, specifically for measures of epithelial immune status. Immune status will be assessed via density of dendritic and non-dendritic immune cells.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Corneal Epithelial Immune Dendritic Cell Density (Temporal Cornea)</measure>
    <time_frame>Six weeks</time_frame>
    <description>The primary statistical objective is to describe differences in efficacy between regimens, specifically for measures of epithelial immune status. Immune status will be assessed via density of dendritic and non-dendritic immune cells.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Corneal Epithelial Immune Non-Dendritic Cell Density (Central Cornea)</measure>
    <time_frame>Six weeks</time_frame>
    <description>The primary statistical objective is to describe differences in efficacy between regimens, specifically for measures of epithelial immune status. Immune status will be assessed via density of dendritic and non-dendritic immune cells.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Corneal Epithelial Immune Non-Dendritic Cell Density (Inferior Cornea)</measure>
    <time_frame>Six weeks</time_frame>
    <description>The primary statistical objective is to describe differences in efficacy between regimens, specifically for measures of epithelial immune status. Immune status will be assessed via density of dendritic and non-dendritic immune cells.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Corneal Epithelial Immune Non-Dendritic Cell Density (Nasal Cornea)</measure>
    <time_frame>Six weeks</time_frame>
    <description>The primary statistical objective is to describe differences in efficacy between regimens, specifically for measures of epithelial immune status. Immune status will be assessed via density of dendritic and non-dendritic immune cells.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Corneal Epithelial Immune Non-Dendritic Cell Density (Superior Cornea)</measure>
    <time_frame>Six weeks</time_frame>
    <description>The primary statistical objective is to describe differences in efficacy between regimens, specifically for measures of epithelial immune status. Immune status will be assessed via density of dendritic and non-dendritic immune cells.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Corneal Epithelial Immune Non-Dendritic Cell Density (Temporal Cornea)</measure>
    <time_frame>Six weeks</time_frame>
    <description>The primary statistical objective is to describe differences in efficacy between regimens, specifically for measures of epithelial immune status. Immune status will be assessed via density of dendritic and non-dendritic immune cells.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Slit-lamp Findings, Corrected Visual Acuity (Snellen) and Adverse Events</measure>
    <time_frame>Six weeks</time_frame>
    <description>The safety analysis will be based on slit-lamp findings, corrected visual acuity (Snellen) and adverse events (if any). No inferential statistical analyses are planned for any safety variable.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Myopia</condition>
  <condition>Refractive Error</condition>
  <arm_group>
    <arm_group_label>OPTI-FREE® RepleniSH®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clear Care®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ReNu MultiPlus® MultiPurpose Solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ReNu MultiPlus® MultiPurpose Solution</intervention_name>
    <description>Contact lens care regimen</description>
    <arm_group_label>ReNu MultiPlus® MultiPurpose Solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPTI-FREE® RepleniSH®</intervention_name>
    <description>Contact Lens care regimen</description>
    <arm_group_label>OPTI-FREE® RepleniSH®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clear Care®</intervention_name>
    <description>Contact lens care regimen</description>
    <arm_group_label>Clear Care®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must be 18 years of age and may be of any race and either gender.

          2. Subjects must not have ever worn contact lenses.

          3. Subjects must have normal, healthy eyes.

        Exclusion Criteria:

          1. Subjects must not use additional lens cleaners.

          2. subjects must not have any ocular or systemic disease.

          3. Subjects must not have history of ocular surgery/trauma within the last 6 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedram Hamrah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts Eye and Ear Infirmary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christine Sindt, OD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-1091</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts Eye and Ear Infirmary</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2010</study_first_submitted>
  <study_first_submitted_qc>November 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2010</study_first_posted>
  <results_first_submitted>April 24, 2013</results_first_submitted>
  <results_first_submitted_qc>November 11, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 10, 2017</results_first_posted>
  <last_update_submitted>November 11, 2016</last_update_submitted>
  <last_update_submitted_qc>November 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Contact lens</keyword>
  <keyword>Lens care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Refractive Errors</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>94 Neophyte contact lens wearers were fitted for one of 3 types of contact lenses (Bausch and Lomb PureVision; Vistakon Acuvue Oasys or Cooper Vision Biofinity) and were then randomized into one of three test articles (care regimens): OptiFree RepleniSH Multi-Purpose Disinfecting Solution, Clear Care or ReNu MultiPlus Multi-Purpose Solution.</recruitment_details>
      <pre_assignment_details>127 subjects were screened, out of which 94 were successfully enrolled and 35 were screenfailed due to non-normal clinical findings. Of the enrolled, 10 did not complete the study visits.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>OPTI-FREE® RepleniSH®</title>
          <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
        </group>
        <group group_id="P2">
          <title>Clear Care®</title>
          <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
        </group>
        <group group_id="P3">
          <title>ReNu MultiPlus® MultiPurpose Solution</title>
          <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>OPTI-FREE® RepleniSH®</title>
          <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
        </group>
        <group group_id="B2">
          <title>Clear Care®</title>
          <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
        </group>
        <group group_id="B3">
          <title>ReNu MultiPlus® MultiPurpose Solution</title>
          <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="32"/>
            <count group_id="B4" value="94"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="94"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.7" spread="10.3"/>
                    <measurement group_id="B2" value="32.9" spread="12.2"/>
                    <measurement group_id="B3" value="30.6" spread="9.1"/>
                    <measurement group_id="B4" value="31.4" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Corneal Epithelial Immune Dendritic Cell Density (Central Cornea)</title>
        <description>The primary statistical objective is to describe differences in efficacy between regimens, specifically for measures of epithelial immune status. Immune status will be assessed via density of dendritic and non-dendritic immune cells.</description>
        <time_frame>Six weeks</time_frame>
        <population>Participants who completed all visits were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>OPTI-FREE® RepleniSH®</title>
            <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
          </group>
          <group group_id="O2">
            <title>Clear Care®</title>
            <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
          </group>
          <group group_id="O3">
            <title>ReNu MultiPlus® MultiPurpose Solution</title>
            <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
          </group>
        </group_list>
        <measure>
          <title>Corneal Epithelial Immune Dendritic Cell Density (Central Cornea)</title>
          <description>The primary statistical objective is to describe differences in efficacy between regimens, specifically for measures of epithelial immune status. Immune status will be assessed via density of dendritic and non-dendritic immune cells.</description>
          <population>Participants who completed all visits were analyzed.</population>
          <units>cells/mm2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.2" spread="9.4"/>
                    <measurement group_id="O2" value="44.8" spread="11.6"/>
                    <measurement group_id="O3" value="62.3" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Slit-lamp Findings, Corrected Visual Acuity (Snellen) and Adverse Events</title>
        <description>The safety analysis will be based on slit-lamp findings, corrected visual acuity (Snellen) and adverse events (if any). No inferential statistical analyses are planned for any safety variable.</description>
        <time_frame>Six weeks</time_frame>
        <population>Participants who completed the study visits were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>OPTI-FREE® RepleniSH®</title>
            <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
          </group>
          <group group_id="O2">
            <title>Clear Care®</title>
            <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
          </group>
          <group group_id="O3">
            <title>ReNu MultiPlus® MultiPurpose Solution</title>
            <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Slit-lamp Findings, Corrected Visual Acuity (Snellen) and Adverse Events</title>
          <description>The safety analysis will be based on slit-lamp findings, corrected visual acuity (Snellen) and adverse events (if any). No inferential statistical analyses are planned for any safety variable.</description>
          <population>Participants who completed the study visits were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Corneal Epithelial Immune Dendritic Cell Density (Inferior Cornea)</title>
        <description>The primary statistical objective is to describe differences in efficacy between regimens, specifically for measures of epithelial immune status. Immune status will be assessed via density of dendritic and non-dendritic immune cells.</description>
        <time_frame>Six weeks</time_frame>
        <population>Participants who completed the study visits were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>OPTI-FREE® RepleniSH®</title>
            <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
          </group>
          <group group_id="O2">
            <title>Clear Care®</title>
            <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
          </group>
          <group group_id="O3">
            <title>ReNu MultiPlus® MultiPurpose Solution</title>
            <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
          </group>
        </group_list>
        <measure>
          <title>Corneal Epithelial Immune Dendritic Cell Density (Inferior Cornea)</title>
          <description>The primary statistical objective is to describe differences in efficacy between regimens, specifically for measures of epithelial immune status. Immune status will be assessed via density of dendritic and non-dendritic immune cells.</description>
          <population>Participants who completed the study visits were analyzed.</population>
          <units>cells/mm2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.0" spread="12.2"/>
                    <measurement group_id="O2" value="90.1" spread="9.7"/>
                    <measurement group_id="O3" value="113.6" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Corneal Epithelial Immune Dendritic Cell Density (Nasal Cornea)</title>
        <description>The primary statistical objective is to describe differences in efficacy between regimens, specifically for measures of epithelial immune status. Immune status will be assessed via density of dendritic and non-dendritic immune cells.</description>
        <time_frame>Six weeks</time_frame>
        <population>Participants who completed the study visits were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>OPTI-FREE® RepleniSH®</title>
            <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
          </group>
          <group group_id="O2">
            <title>Clear Care®</title>
            <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
          </group>
          <group group_id="O3">
            <title>ReNu MultiPlus® MultiPurpose Solution</title>
            <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
          </group>
        </group_list>
        <measure>
          <title>Corneal Epithelial Immune Dendritic Cell Density (Nasal Cornea)</title>
          <description>The primary statistical objective is to describe differences in efficacy between regimens, specifically for measures of epithelial immune status. Immune status will be assessed via density of dendritic and non-dendritic immune cells.</description>
          <population>Participants who completed the study visits were analyzed.</population>
          <units>cells/mm2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.7" spread="8.6"/>
                    <measurement group_id="O2" value="67.8" spread="8.1"/>
                    <measurement group_id="O3" value="73.6" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Corneal Epithelial Immune Dendritic Cell Density (Superior Cornea)</title>
        <description>The primary statistical objective is to describe differences in efficacy between regimens, specifically for measures of epithelial immune status. Immune status will be assessed via density of dendritic and non-dendritic immune cells.</description>
        <time_frame>Six weeks</time_frame>
        <population>Participants who completed the study visits were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>OPTI-FREE® RepleniSH®</title>
            <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
          </group>
          <group group_id="O2">
            <title>Clear Care®</title>
            <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
          </group>
          <group group_id="O3">
            <title>ReNu MultiPlus® MultiPurpose Solution</title>
            <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
          </group>
        </group_list>
        <measure>
          <title>Corneal Epithelial Immune Dendritic Cell Density (Superior Cornea)</title>
          <description>The primary statistical objective is to describe differences in efficacy between regimens, specifically for measures of epithelial immune status. Immune status will be assessed via density of dendritic and non-dendritic immune cells.</description>
          <population>Participants who completed the study visits were analyzed.</population>
          <units>cells/mm2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.1" spread="15.2"/>
                    <measurement group_id="O2" value="92.5" spread="9.3"/>
                    <measurement group_id="O3" value="106.1" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Corneal Epithelial Immune Dendritic Cell Density (Temporal Cornea)</title>
        <description>The primary statistical objective is to describe differences in efficacy between regimens, specifically for measures of epithelial immune status. Immune status will be assessed via density of dendritic and non-dendritic immune cells.</description>
        <time_frame>Six weeks</time_frame>
        <population>Participants who completed the study visits were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>OPTI-FREE® RepleniSH®</title>
            <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
          </group>
          <group group_id="O2">
            <title>Clear Care®</title>
            <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
          </group>
          <group group_id="O3">
            <title>ReNu MultiPlus® MultiPurpose Solution</title>
            <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
          </group>
        </group_list>
        <measure>
          <title>Corneal Epithelial Immune Dendritic Cell Density (Temporal Cornea)</title>
          <description>The primary statistical objective is to describe differences in efficacy between regimens, specifically for measures of epithelial immune status. Immune status will be assessed via density of dendritic and non-dendritic immune cells.</description>
          <population>Participants who completed the study visits were analyzed.</population>
          <units>cells/mm2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.2" spread="12.2"/>
                    <measurement group_id="O2" value="59.0" spread="8.8"/>
                    <measurement group_id="O3" value="58.7" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Corneal Epithelial Immune Non-Dendritic Cell Density (Central Cornea)</title>
        <description>The primary statistical objective is to describe differences in efficacy between regimens, specifically for measures of epithelial immune status. Immune status will be assessed via density of dendritic and non-dendritic immune cells.</description>
        <time_frame>Six weeks</time_frame>
        <population>Participants who completed all visits were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>OPTI-FREE® RepleniSH®</title>
            <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
          </group>
          <group group_id="O2">
            <title>Clear Care®</title>
            <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
          </group>
          <group group_id="O3">
            <title>ReNu MultiPlus® MultiPurpose Solution</title>
            <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
          </group>
        </group_list>
        <measure>
          <title>Corneal Epithelial Immune Non-Dendritic Cell Density (Central Cornea)</title>
          <description>The primary statistical objective is to describe differences in efficacy between regimens, specifically for measures of epithelial immune status. Immune status will be assessed via density of dendritic and non-dendritic immune cells.</description>
          <population>Participants who completed all visits were analyzed.</population>
          <units>cells/mm2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.2"/>
                    <measurement group_id="O2" value="0.4" spread="0.2"/>
                    <measurement group_id="O3" value="0.4" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Corneal Epithelial Immune Non-Dendritic Cell Density (Inferior Cornea)</title>
        <description>The primary statistical objective is to describe differences in efficacy between regimens, specifically for measures of epithelial immune status. Immune status will be assessed via density of dendritic and non-dendritic immune cells.</description>
        <time_frame>Six weeks</time_frame>
        <population>Participants who completed all visits were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>OPTI-FREE® RepleniSH®</title>
            <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
          </group>
          <group group_id="O2">
            <title>Clear Care®</title>
            <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
          </group>
          <group group_id="O3">
            <title>ReNu MultiPlus® MultiPurpose Solution</title>
            <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
          </group>
        </group_list>
        <measure>
          <title>Corneal Epithelial Immune Non-Dendritic Cell Density (Inferior Cornea)</title>
          <description>The primary statistical objective is to describe differences in efficacy between regimens, specifically for measures of epithelial immune status. Immune status will be assessed via density of dendritic and non-dendritic immune cells.</description>
          <population>Participants who completed all visits were analyzed.</population>
          <units>cells/mm2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.2"/>
                    <measurement group_id="O2" value="0.5" spread="0.2"/>
                    <measurement group_id="O3" value="0.7" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Corneal Epithelial Immune Non-Dendritic Cell Density (Nasal Cornea)</title>
        <description>The primary statistical objective is to describe differences in efficacy between regimens, specifically for measures of epithelial immune status. Immune status will be assessed via density of dendritic and non-dendritic immune cells.</description>
        <time_frame>Six weeks</time_frame>
        <population>Participants who completed all visits were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>OPTI-FREE® RepleniSH®</title>
            <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
          </group>
          <group group_id="O2">
            <title>Clear Care®</title>
            <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
          </group>
          <group group_id="O3">
            <title>ReNu MultiPlus® MultiPurpose Solution</title>
            <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
          </group>
        </group_list>
        <measure>
          <title>Corneal Epithelial Immune Non-Dendritic Cell Density (Nasal Cornea)</title>
          <description>The primary statistical objective is to describe differences in efficacy between regimens, specifically for measures of epithelial immune status. Immune status will be assessed via density of dendritic and non-dendritic immune cells.</description>
          <population>Participants who completed all visits were analyzed.</population>
          <units>cells/mm2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.9"/>
                    <measurement group_id="O2" value="1.2" spread="0.5"/>
                    <measurement group_id="O3" value="1.1" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Corneal Epithelial Immune Non-Dendritic Cell Density (Superior Cornea)</title>
        <description>The primary statistical objective is to describe differences in efficacy between regimens, specifically for measures of epithelial immune status. Immune status will be assessed via density of dendritic and non-dendritic immune cells.</description>
        <time_frame>Six weeks</time_frame>
        <population>Participants who completed all visits were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>OPTI-FREE® RepleniSH®</title>
            <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
          </group>
          <group group_id="O2">
            <title>Clear Care®</title>
            <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
          </group>
          <group group_id="O3">
            <title>ReNu MultiPlus® MultiPurpose Solution</title>
            <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
          </group>
        </group_list>
        <measure>
          <title>Corneal Epithelial Immune Non-Dendritic Cell Density (Superior Cornea)</title>
          <description>The primary statistical objective is to describe differences in efficacy between regimens, specifically for measures of epithelial immune status. Immune status will be assessed via density of dendritic and non-dendritic immune cells.</description>
          <population>Participants who completed all visits were analyzed.</population>
          <units>cells/mm2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.1"/>
                    <measurement group_id="O2" value="0.6" spread="0.2"/>
                    <measurement group_id="O3" value="0.3" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Corneal Epithelial Immune Non-Dendritic Cell Density (Temporal Cornea)</title>
        <description>The primary statistical objective is to describe differences in efficacy between regimens, specifically for measures of epithelial immune status. Immune status will be assessed via density of dendritic and non-dendritic immune cells.</description>
        <time_frame>Six weeks</time_frame>
        <population>Participants who completed all visits were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>OPTI-FREE® RepleniSH®</title>
            <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
          </group>
          <group group_id="O2">
            <title>Clear Care®</title>
            <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
          </group>
          <group group_id="O3">
            <title>ReNu MultiPlus® MultiPurpose Solution</title>
            <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
          </group>
        </group_list>
        <measure>
          <title>Corneal Epithelial Immune Non-Dendritic Cell Density (Temporal Cornea)</title>
          <description>The primary statistical objective is to describe differences in efficacy between regimens, specifically for measures of epithelial immune status. Immune status will be assessed via density of dendritic and non-dendritic immune cells.</description>
          <population>Participants who completed all visits were analyzed.</population>
          <units>cells/mm2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.2"/>
                    <measurement group_id="O2" value="0.7" spread="0.3"/>
                    <measurement group_id="O3" value="0.8" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Six weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>OPTI-FREE® RepleniSH®</title>
          <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
        </group>
        <group group_id="E2">
          <title>Clear Care®</title>
          <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
        </group>
        <group group_id="E3">
          <title>ReNu MultiPlus® MultiPurpose Solution</title>
          <description>33 participants will be assigned to use this lens care regimen during the six-week assessment period</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Pedram Hamrah</name_or_title>
      <organization>Massachusetts Eye and Ear Infirmary</organization>
      <phone>617-573-3313</phone>
      <email>cornea_research@meei.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

